KEFLET
LOE ApproachingNDAORALTABLET
Approved
Oct 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEFLET is an oral tablet small-molecule NDA approved by Eli Lilly in 1972. The generic name and mechanism of action are not publicly available in this dataset. The specific indications and therapeutic area are unknown.
LOE Approaching
Product is in advanced lifecycle phase with approaching loss of exclusivity, suggesting smaller commercial team and focus on generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KEFLET currently has zero linked job opportunities, reflecting its late-lifecycle stage and approaching loss of exclusivity. Career roles on this product focus on defensive strategies, regulatory compliance, and managing the transition to generic competition rather than growth-oriented innovation.
Product Manager (Legacy)Supply Chain Specialist
Worked on KEFLET at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.